Dr. Lara on the Role of Sunitinib for Renal Cell Carcinoma

Primo N. Lara, MD
Published: Wednesday, Aug 02, 2017



Primo N. Lara, MD, associate director for translational research, UC Davis Comprehensive Cancer Center, discusses the role of sunitinib (Sutent) for patients with renal cell carcinoma (RCC).

Sunitinib was shown in the S-TRAC trial to modestly improve disease-free survival for patients with completely resected RCC, explains Lara. Sunitinib as an adjuvant therapy has considerable toxicities that need to be managed.

According to Lara, even though sunitinib did see an increase in disease-free survival it had no clear benefit in terms of overall survival.



Primo N. Lara, MD, associate director for translational research, UC Davis Comprehensive Cancer Center, discusses the role of sunitinib (Sutent) for patients with renal cell carcinoma (RCC).

Sunitinib was shown in the S-TRAC trial to modestly improve disease-free survival for patients with completely resected RCC, explains Lara. Sunitinib as an adjuvant therapy has considerable toxicities that need to be managed.

According to Lara, even though sunitinib did see an increase in disease-free survival it had no clear benefit in terms of overall survival.


View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Cancer Summaries and Commentaries™: Update from Chicago: Advances in the Treatment of Breast CancerJul 31, 20181.0
Community Practice Connections™: The Next Generation in Renal Cell Carcinoma Treatment: An Oncology Nursing Essentials WorkshopJul 31, 20181.5
Publication Bottom Border
Border Publication
x